LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Abierto

2.7 -4.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.7

Máximo

2.9699999999999998

Métricas clave
By Trading Economics
Ingresos	64M 57M
Ventas	65M 67M
P/B Media del Sector	7.135 49.8
Margen de beneficios	84.425
Empleados	75
EBITDA	63M 56M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+62.72% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	38M 250M
Apertura anterior	7.29
Cierre anterior	2.7

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.25 / 1.48 Soporte y Resistencia

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 may 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 may 2026, 23:46 UTC

Charlas de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 may 2026, 23:33 UTC

Charlas de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 may 2026, 22:37 UTC

Charlas de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 may 2026, 22:32 UTC

Ganancias

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 may 2026, 22:02 UTC

Charlas de Mercado

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 may 2026, 21:49 UTC

Ganancias

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 may 2026, 21:42 UTC

Charlas de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 may 2026, 21:23 UTC

Adquisiciones, fusiones, absorciones

CSG Systems Sale to NEC Gets CFIUS Clearance

11 may 2026, 21:12 UTC

Ganancias

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 may 2026, 21:12 UTC

Ganancias

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

11 may 2026, 20:44 UTC

Ganancias

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 may 2026, 20:43 UTC

Ganancias

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Rev $136.4M >CLSK

11 may 2026, 20:30 UTC

Ganancias

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Cont Ops EPS $2.24 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Rev $1.6B >STE

11 may 2026, 20:30 UTC

Ganancias

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Adj EPS $2.83 >STE

11 may 2026, 20:22 UTC

Acciones populares

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 may 2026, 19:37 UTC

Ganancias

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 may 2026, 19:32 UTC

Charlas de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

62.72% repunte

Estimación a 12 Meses

Media 4.67 USD 62.72%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.25 / 1.48Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.